Partner Therapeutics, Inc.
Company profile
Partner Therapeutics, Inc.
partnertx.comHeadquarters: United States
51-200 employeesHybrid (Product + Service)
Primary focus
Development, manufacturing and commercialization of late-stage biologic therapeutics, with emphasis on oncology, immunomodulation and medical countermeasures.
Why it’s included
The profile explicitly states that Partner Therapeutics develops and manufactures Leukine (sargramostim), which is FDA-approved for treating hematological damage due to acute radiation exposure, and cites BARDA funding for its advanced development as a medical countermeasure for radiation injury.
Relevant capabilities
- Host-directed immunomodulatory therapy development (recombinant GM-CSF)
- Preclinical in vivo efficacy models and animal studies
- GMP-compliant biologics manufacturing and facility operation
- Development and commercialization of late-stage biologic therapeutics
- Scale-up and expansion of manufacturing capacity for surge demand
Commercial sectorHematopoietic & Systemic ARS Countermeasure Therapeutics
Technology classesHematopoietic growth factor biologics (G-CSF, GM-CSF)
Relevant commercial products
- Leukine (sargramostim)
- IMREPLYS
- Zenocutuzumab (targeted antibody for NRG1 fusion-positive cancers)
- BIZENGRI